Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Advanced Medical Solutions ( (GB:AMS) ).
Advanced Medical Solutions Group plc reported strong interim results for the first half of 2025, with a 63% increase in group revenue to £110.8 million, driven by the acquisition of Peters Surgical and organic growth. The integration of Peters Surgical and Syntacoll has contributed positively, enhancing manufacturing efficiencies and expanding market presence, particularly in cardiovascular markets. Despite a slight reduction in gross margins, the company achieved a 42% increase in adjusted EBITDA and a 49% rise in profit before tax. The restructuring of the Woundcare business has been completed, positioning it as a cash-generative unit. AMS remains optimistic about sustaining growth, with plans for US product launches and further deleveraging by year-end.
The most recent analyst rating on (GB:AMS) stock is a Hold with a £216.00 price target. To see the full list of analyst forecasts on Advanced Medical Solutions stock, see the GB:AMS Stock Forecast page.
Spark’s Take on GB:AMS Stock
According to Spark, TipRanks’ AI Analyst, GB:AMS is a Neutral.
The overall stock score of 62 reflects strong revenue growth and a solid capital structure, but is tempered by declining profitability margins and high valuation. Technical indicators suggest a neutral trend, with no significant bullish or bearish signals. The high P/E ratio indicates potential overvaluation, while the dividend yield offers limited income potential.
To see Spark’s full report on GB:AMS stock, click here.
More about Advanced Medical Solutions
Advanced Medical Solutions Group plc (AMS) is a leading independent developer and manufacturer specializing in innovative tissue-healing technologies. The company offers a diverse range of surgical products, including tissue adhesives, sutures, haemostats, internal fixation devices, and sealants, marketed under brands such as LiquiBand®, RESORBA®, and Peters Surgical. AMS also provides wound care dressings like silver alginates and foams, focusing on delivering quality outcomes for patients and value for payers.
Average Trading Volume: 409,188
Technical Sentiment Signal: Sell
Current Market Cap: £460.4M
Find detailed analytics on AMS stock on TipRanks’ Stock Analysis page.